查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1546231

蛋白質結合檢測的全球市場

Protein Binding Assays
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

到 2030 年，全球蛋白質結合檢測市場預計將達到 8.349 億美元

蛋白質結合檢測的全球市場預計 2023 年為 4.442 億美元，預計到 2030 年將達到 8.349 億美元，在 2023-2030 年分析期間複合年成長率為 9.4%。平衡透析技術是本報告分析的細分市場之一，預計複合年成長率為 9.6%，到分析期結束時將達到 3.422 億美元。分析期間內，超過濾技術領域的複合年成長率預計為 9.8%。

美國市場預估為1.209億美元，中國預期複合年成長率為8.7%

到 2023 年，美國蛋白質結合檢測市場預計將達到 1.209 億美元。中國作為全球第二大經濟體，預計2030年市場規模將達1.277億美元，2023年至2030年複合年成長率為8.7%。其他值得注意的區域市場包括日本和加拿大，在分析期間預計複合年成長率分別為 8.2% 和 8.0%。在歐洲，德國預計複合年成長率為 7.3%。

全球蛋白質結合分析市場－主要趨勢與促進因素總結

了解不斷擴大的蛋白質結合檢測市場的複雜性

蛋白質結合測定是藥物發現和開發的重要工具，為藥物與標靶蛋白之間的相互作用提供重要見解。這些測定幫助研究人員確定與蛋白質的結合親和性，這對於了解藥物的藥物動力學、動態和整體功效非常重要。製藥和生物技術產業在藥物開發的早期階段嚴重依賴這些檢測來篩檢潛在的候選藥物並最佳化先導化合物。隨著個人化醫療需求的增加，蛋白質結合測定在針對特定患者群體的藥物的識別和開發中發揮著越來越重要的作用，使其成為現代醫療保健的重要組成部分。

技術進步如何提高測定的準確性和效率？

技術進步顯著提高了蛋白質結合測定的準確性、靈敏度和效率。高通量篩檢（HTS）技術的發展使得能夠同時分析數千種化合物，加速了藥物發現過程。此外，表面等離子共振（SPR）和等溫滴定量熱法（ITC）等無標定檢測方法的創新可以更精確地測量結合相互作用，而無需螢光或放射性標記。這些進步不僅提高了蛋白質結合測定產生的資料的可靠性，而且還減少了與藥物開發相關的時間和成本。此外，人工智慧 (AI) 和機器學習演算法的整合正在增強這些檢測的預測能力，使它們能夠更準確地識別潛在的候選藥物。

監理合規在市場中扮演什麼角色？

法規遵循是推動製藥和生物技術產業採用先進蛋白質結合測定的關鍵因素。美國食品藥物管理局(FDA) 和歐洲藥品管理局 (EMA) 等監管機構要求提供有關藥物-蛋白質交互作用的全面資料，作為醫藥品認證過程的一部分。這增加了對提供準確和可重複結果並確保藥物安全性和有效性的檢測的需求。藥品核准的嚴格要求正在推動公司採用最新的檢測技術和方法，進一步推動該領域的創新。此外，對需要詳細表徵蛋白質結合特性的生物相似藥和生技藥品的日益關注進一步推動了對先進蛋白質結合測定的需求。

市場成長的主要驅動力是什麼？

蛋白質結合測定市場的成長是由多種因素推動的。對個人化醫療和標靶治療的需求不斷成長，推動了對更準確、更可靠的蛋白質結合測定的需求。高通量篩檢技術和無標定檢測方法的發展等技術進步極大地提高了這些測定的效率和精確度，促進了它們在藥物發現和藥物開發中的採用。隨著公司尋求確保遵守嚴格的安全性和有效性標準，對藥物-蛋白質相互作用的全面資料的監管要求也將發揮關鍵的市場驅動力。此外，對需要詳細表徵蛋白質的生技藥品和生物相似藥的日益關注進一步推動了對蛋白質結合測定的需求。

受訪企業範例（44家知名企業）

  • Absorption Systems LLC
  • ADMEcell, Inc.
  • Biotium, Inc.
  • Danaher Corporation
  • Eurofins Scientific
  • GE Healthcare Life Sciences
  • HTDialysis, LLC
  • Merck & Co., Inc.
  • Sovicell GmbH
  • Thermo Fisher Scientific, Inc.

目錄

第1章調查方法

第 2 章執行摘要

  • 市場概況
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲國家
  • 亞太地區
  • 其他領域

第4章 比賽

簡介目錄
Product Code: MCP14257

Global Protein Binding Assays Market to Reach US$834.9 Million by 2030

The global market for Protein Binding Assays estimated at US$444.2 Million in the year 2023, is expected to reach US$834.9 Million by 2030, growing at a CAGR of 9.4% over the analysis period 2023-2030. Equilibrium Dialysis Technology, one of the segments analyzed in the report, is expected to record a 9.6% CAGR and reach US$342.2 Million by the end of the analysis period. Growth in the Ultrafiltration Technology segment is estimated at 9.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$120.9 Million While China is Forecast to Grow at 8.7% CAGR

The Protein Binding Assays market in the U.S. is estimated at US$120.9 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$127.7 Million by the year 2030 trailing a CAGR of 8.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.2% and 8.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.3% CAGR.

Global Protein Binding Assays Market - Key Trends and Drivers Summarized

Understanding the Complexities: The Expanding Market for Protein Binding Assays

Protein binding assays are crucial tools in drug discovery and development, providing essential insights into the interactions between drugs and their target proteins. These assays help researchers determine the binding affinity of a drug to a protein, which is critical for understanding its pharmacokinetics, pharmacodynamics, and overall efficacy. The pharmaceutical and biotechnology industries heavily rely on these assays during the early stages of drug development to screen potential drug candidates and optimize lead compounds. As the demand for personalized medicine grows, protein binding assays play an increasingly vital role in identifying and developing drugs tailored to specific patient populations, making them indispensable in modern healthcare.

How Are Technological Advancements Enhancing Assay Accuracy and Efficiency?

Technological advancements have significantly improved the accuracy, sensitivity, and efficiency of protein binding assays. The development of high-throughput screening (HTS) technologies has enabled the simultaneous analysis of thousands of compounds, accelerating the drug discovery process. Additionally, innovations in label-free detection methods, such as surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC), have provided more precise measurements of binding interactions without the need for fluorescent or radioactive labels. These advancements have not only improved the reliability of the data generated by protein binding assays but have also reduced the time and cost associated with drug development. Furthermore, the integration of artificial intelligence (AI) and machine learning algorithms is enhancing the predictive capabilities of these assays, allowing for more accurate identification of potential drug candidates.

What Role Does Regulatory Compliance Play in the Market?

Regulatory compliance is a significant factor driving the adoption of advanced protein binding assays in the pharmaceutical and biotechnology industries. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) require comprehensive data on drug-protein interactions as part of the drug approval process. This has led to an increased demand for assays that provide accurate and reproducible results, ensuring that drugs are both safe and effective. The stringent requirements for drug approval have pushed companies to adopt the latest assay technologies and methodologies, further driving innovation in the field. Additionally, the growing focus on biosimilars and biologics, which require detailed characterization of protein binding properties, has further increased the demand for advanced protein binding assays.

What Are the Key Growth Drivers in the Market?

The growth in the protein binding assays market is driven by several factors. The increasing demand for personalized medicine and targeted therapies has spurred the need for more accurate and reliable protein binding assays. Technological advancements, such as the development of high-throughput screening technologies and label-free detection methods, have significantly improved the efficiency and accuracy of these assays, driving their adoption in drug discovery and development. Regulatory requirements for comprehensive data on drug-protein interactions have also played a crucial role in driving the market, as companies seek to ensure compliance with stringent safety and efficacy standards. Additionally, the growing focus on biologics and biosimilars, which require detailed protein characterization, is further propelling the demand for protein binding assays.

Select Competitors (Total 44 Featured) -

  • Absorption Systems LLC
  • ADMEcell, Inc.
  • Biotium, Inc.
  • Danaher Corporation
  • Eurofins Scientific
  • GE Healthcare Life Sciences
  • HTDialysis, LLC
  • Merck & Co., Inc.
  • Sovicell GmbH
  • Thermo Fisher Scientific, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Protein Binding Assays - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand in Drug Discovery and Development Propels Market Growth
    • Increasing Use in Pharmacokinetics Expands Addressable Market Opportunity
    • Technological Advancements in High-Throughput Screening Strengthen Market Position
    • Growing Focus on Personalized Medicine Drives Adoption of Protein Binding Assays
    • Surge in Demand for Accurate and Reliable Assay Technologies Generates New Opportunities
    • Development of Novel Assay Formats Sustains Market Growth
    • Expanding Applications in Toxicology Testing Throws Spotlight on Market Potential
    • Surge in Demand for Assays in Biologics Development Expands Market Horizons
    • Growing Awareness of Drug-Protein Interactions Drives Market Adoption
    • Innovations in Label-Free Detection Technologies Generate New Market Opportunities
    • Rising Use of Protein Binding Assays in Clinical research Throws Spotlight on Market Dynamics
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Protein Binding Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 2: World 7-Year Perspective for Protein Binding Assays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
    • TABLE 3: World Recent Past, Current & Future Analysis for Equilibrium Dialysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 4: World 7-Year Perspective for Equilibrium Dialysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Ultrafiltration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World 7-Year Perspective for Ultrafiltration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Ultracentrifugation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 8: World 7-Year Perspective for Ultracentrifugation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 9: World Protein Binding Assays Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 11: World 7-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 13: World 7-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World 7-Year Perspective for Contract Research Organizations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Research & Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 17: World 7-Year Perspective for Research & Diagnostic Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Protein Binding Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 18: USA Recent Past, Current & Future Analysis for Protein Binding Assays by Technology - Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 19: USA 7-Year Perspective for Protein Binding Assays by Technology - Percentage Breakdown of Value Sales for Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies for the Years 2024 & 2030
    • TABLE 20: USA Recent Past, Current & Future Analysis for Protein Binding Assays by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: USA 7-Year Perspective for Protein Binding Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories for the Years 2024 & 2030
  • CANADA
    • TABLE 22: Canada Recent Past, Current & Future Analysis for Protein Binding Assays by Technology - Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 23: Canada 7-Year Perspective for Protein Binding Assays by Technology - Percentage Breakdown of Value Sales for Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies for the Years 2024 & 2030
    • TABLE 24: Canada Recent Past, Current & Future Analysis for Protein Binding Assays by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 25: Canada 7-Year Perspective for Protein Binding Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories for the Years 2024 & 2030
  • JAPAN
    • Protein Binding Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 26: Japan Recent Past, Current & Future Analysis for Protein Binding Assays by Technology - Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Japan 7-Year Perspective for Protein Binding Assays by Technology - Percentage Breakdown of Value Sales for Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies for the Years 2024 & 2030
    • TABLE 28: Japan Recent Past, Current & Future Analysis for Protein Binding Assays by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 29: Japan 7-Year Perspective for Protein Binding Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories for the Years 2024 & 2030
  • CHINA
    • Protein Binding Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 30: China Recent Past, Current & Future Analysis for Protein Binding Assays by Technology - Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 31: China 7-Year Perspective for Protein Binding Assays by Technology - Percentage Breakdown of Value Sales for Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies for the Years 2024 & 2030
    • TABLE 32: China Recent Past, Current & Future Analysis for Protein Binding Assays by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: China 7-Year Perspective for Protein Binding Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories for the Years 2024 & 2030
  • EUROPE
    • Protein Binding Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 34: Europe Recent Past, Current & Future Analysis for Protein Binding Assays by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 35: Europe 7-Year Perspective for Protein Binding Assays by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
    • TABLE 36: Europe Recent Past, Current & Future Analysis for Protein Binding Assays by Technology - Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 37: Europe 7-Year Perspective for Protein Binding Assays by Technology - Percentage Breakdown of Value Sales for Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies for the Years 2024 & 2030
    • TABLE 38: Europe Recent Past, Current & Future Analysis for Protein Binding Assays by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Europe 7-Year Perspective for Protein Binding Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories for the Years 2024 & 2030
  • FRANCE
    • Protein Binding Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 40: France Recent Past, Current & Future Analysis for Protein Binding Assays by Technology - Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 41: France 7-Year Perspective for Protein Binding Assays by Technology - Percentage Breakdown of Value Sales for Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies for the Years 2024 & 2030
    • TABLE 42: France Recent Past, Current & Future Analysis for Protein Binding Assays by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 43: France 7-Year Perspective for Protein Binding Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories for the Years 2024 & 2030
  • GERMANY
    • Protein Binding Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 44: Germany Recent Past, Current & Future Analysis for Protein Binding Assays by Technology - Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Germany 7-Year Perspective for Protein Binding Assays by Technology - Percentage Breakdown of Value Sales for Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies for the Years 2024 & 2030
    • TABLE 46: Germany Recent Past, Current & Future Analysis for Protein Binding Assays by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 47: Germany 7-Year Perspective for Protein Binding Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories for the Years 2024 & 2030
  • ITALY
    • TABLE 48: Italy Recent Past, Current & Future Analysis for Protein Binding Assays by Technology - Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 49: Italy 7-Year Perspective for Protein Binding Assays by Technology - Percentage Breakdown of Value Sales for Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies for the Years 2024 & 2030
    • TABLE 50: Italy Recent Past, Current & Future Analysis for Protein Binding Assays by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Italy 7-Year Perspective for Protein Binding Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories for the Years 2024 & 2030
  • UNITED KINGDOM
    • Protein Binding Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 52: UK Recent Past, Current & Future Analysis for Protein Binding Assays by Technology - Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 53: UK 7-Year Perspective for Protein Binding Assays by Technology - Percentage Breakdown of Value Sales for Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies for the Years 2024 & 2030
    • TABLE 54: UK Recent Past, Current & Future Analysis for Protein Binding Assays by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 55: UK 7-Year Perspective for Protein Binding Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories for the Years 2024 & 2030
  • REST OF EUROPE
    • TABLE 56: Rest of Europe Recent Past, Current & Future Analysis for Protein Binding Assays by Technology - Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Rest of Europe 7-Year Perspective for Protein Binding Assays by Technology - Percentage Breakdown of Value Sales for Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies for the Years 2024 & 2030
    • TABLE 58: Rest of Europe Recent Past, Current & Future Analysis for Protein Binding Assays by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 59: Rest of Europe 7-Year Perspective for Protein Binding Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories for the Years 2024 & 2030
  • ASIA-PACIFIC
    • Protein Binding Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 60: Asia-Pacific Recent Past, Current & Future Analysis for Protein Binding Assays by Technology - Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 61: Asia-Pacific 7-Year Perspective for Protein Binding Assays by Technology - Percentage Breakdown of Value Sales for Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies for the Years 2024 & 2030
    • TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for Protein Binding Assays by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Asia-Pacific 7-Year Perspective for Protein Binding Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories for the Years 2024 & 2030
  • REST OF WORLD
    • TABLE 64: Rest of World Recent Past, Current & Future Analysis for Protein Binding Assays by Technology - Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 65: Rest of World 7-Year Perspective for Protein Binding Assays by Technology - Percentage Breakdown of Value Sales for Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies for the Years 2024 & 2030
    • TABLE 66: Rest of World Recent Past, Current & Future Analysis for Protein Binding Assays by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 67: Rest of World 7-Year Perspective for Protein Binding Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories for the Years 2024 & 2030

IV. COMPETITION